Abstract: This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.

Abstract: A compound represented by the formula: wherein A is thiazolyl or the like, X is a bond or the like, m is an integer of 0 to 4, Y is optionally substituted alkyl or the like, Z is a substituent represented by the formula: wherein R3 is hydrogen atom or the like, R4 and R5 are each independently hydrogen atom or the like, W is —(CH2)n— (n is 0, 1, 2 or 3) or the like, a prodrug thereof, its pharmaceutically acceptable salt, or its solvate is useful as a composition for prevention or treatment of Parkinson's disease.

Abstract: New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R1 is independently alkyl (1–6C); each n is independently an integer of 0–6; and R2 is vinyl or a derivative form thereof.

Abstract: The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.

Abstract: Methods and compositions for staining based upon nucleic acid sequence that employ nucleic acid probes are provided. Said methods produce staining patterns that can be tailored for specific cytogenetic analyses. Said probes are appropriate for in situ hybridization and stain both interphase and metaphase chromosomal material with reliable signals. The nucleic acid probes are typically of a complexity greater than 50 kb, the complexity depending upon the cytogenetic application. Methods and reagents are provided for the detection of genetic rearrangements. Probes and test kits are provided for use in detecting genetic rearrangements, particularly for use in tumor cytogenetics, in the detection of disease related loci, specifically cancer, such as chronic myelogenous leukemia (CML), retinoblastoma, ovarian and uterine cancers, and for biological dosimetry.

Abstract: One disclosed method of processing gene sequence data includes the steps of reading gene sequence data corresponding to a gene sequence and coding sequence data corresponding to a plurality of coding sequences within the gene sequence; identifying and storing, by following a set of primer selection rules, primer pair data within the gene sequence data for one of the coding sequences; repeating the acts of identifying and storing such that primer pair data are obtained for each sequence of the plurality of coding sequences; and simultaneously amplifying the plurality of coding sequences in gene sequences from three or more of individuals using the identified pairs of primer sequences. The set of primer selection rules include a rule specifying that all of the primer pair data for the plurality of coding sequences be obtained for a predetermined annealing temperature, which allows for the subsequent simultaneous amplification of sequences from hundreds of individuals in a single amplification run.

Abstract: The invention relates to compositions and methods useful in the detection of nucleic acids using a variety of amplification techniques, including both signal amplification and target amplification. Detection proceeds through the use of an electron transfer moiety (ETM) that is associated with the nucleic acid, either directly or indirectly, to allow electronic detection of the ETM using an electrode.

Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

Abstract: The present invention involves the pooling of multiple high content cell-based screening assays, and carrying out a primary screen in a one or more channels of a fluorescence detection device, which drastically increases the number of simultaneous high content cell-based screening events that can be carried out. Subsequent deconvolution of primary screen “hits” (ie: those wells or locations on an array of locations in which the one or more test compounds caused a change in the fluorescence signal(s) from the fluorescent reporter molecules in the cells) enables much more rapid generation of high content cell screening data than was previously possible, and at significantly reduced costs.

Abstract: Provided are structure coordinates relating to MvaS and its various uses.

Abstract: The present invention relates to the use of a variety of methods for generating functional thioredoxin reductase variants in which at least one physical, chemical or biological property of the variant is altered in a specific and desired manner when compared to the wild-type protein.

Abstract: The invention relates to compositions and methods for decoding microsphere array sensors.

Abstract: An electrical connection structure that is able to electrically connect wiring to a biopolymer, a production method of the electrical connection structure, and an electric wiring method which is able to perform wiring on a nanometer-scale. A first aspect of the production method of the present invention uses a carbon nanotube as an electrode, and makes the carbon nanotube contact the biopolymer. A second aspect of the production method applies electric current between the electrode and the biopolymer of the first aspect. The electrical connection structure of the present invention comprises at least the electrode formed by the carbon nanotube and the biopolymer, wherein the electrode is in contact with the biopolymer. In the electric wiring method of the present invention, the electrode formed by the carbon nanotube contacts the biopolymer to complete an electrical connection.

Abstract: This invention provides improved polyamides comprising a hairpin loop derived from ?-aminobutyric acid which bind to the minor groove of a promoter regions of a DNA sequence. Binding of the polyamide to the DNA sequence of the promoter region inhibits expression of the requisite gene. The improvement relates to the use of R-2,4-diaminobutyric acid and derivatives of the 2-amino group to form the hairpin loop. The improved asymmetric hairpin provides for tighter binding of the polyamides to the minor groove of DNA and additionally provides an amine function for derivatizing polyamides by, for example, forming amide linkages. Such derivatives may serve to attach detectable labels to the polyamide.

Abstract: Many Gram-negative pathogens assemble adhesive pili structures on their surfaces that allow them to colonize host tissues and cause disease. The present invention relates to novel compounds that mimic a chaperone G1 beta-strand or an amino terminal motif of a pilus subunit. The present invention also relates to the complex formed from the binding of such mimic compounds to the hydrophobic groove of a pilus subunit. Competitively interacting with the binding site of pili subunits will negatively affect the chaperone/usher pathway, which is one molecular mechanism by which Gram-negative bacteria assemble adhesive pili structures, and thus prevent or inhibit pilus assembly.

Abstract: According to the present invention, there is provided a biochemical examination method of supplying a solution of a first biochemical material into an array of which respective second biochemical materials are held, and using a marker by a luminescent molecule to detect a luminescent intensity of the luminescent molecule for each probe array element of the array with an array type detector, so that a reaction state of the first biochemical material with the second biochemical materials is examined for each probe array element, the method comprising: irradiating a reference array by which the luminescent molecule is held with an excitation lighting to photograph a reference light image; irradiating the array for biochemical examination with the same excitation lighting to photograph a sample light image; and correcting the sample light image with the reference light image.

Abstract: The present invention provides methods for predicting the likelihood of development of systemic lupus erythematosus (SLE) in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding Fc?RIIB. The invention also provides isolated nucleic acids encoding Fc?RIIB polymorphisms, nucleic acid probes that hybridize to polymorphic positions and kits for the prediction of SLE status.

Abstract: A method for rapid identification of biological materials is presented, which exploits the wealth of information contained in genome and protein sequence databases (5). In a preferred embodiment, the method utilizes the masses of a set of ions by MALDI TOF mass spectrometry of intact or treated cells (1). Subsequent correlation (4) of each ion in the set to a protein, along with the organismic source of the protein, is performed by searching a database comprising protein molecular weights (9).

Abstract: The present invention provides novel methods to identify, classify, quantify and compare nucleic acids and polypeptides.

Abstract: The present invention relates to a method for regulating the permeability of the blood brain barrier by administering a NOS-3 inhibitor to reduce the increased permeability of the blood brain barrier caused by a pathological condition or by administering a NOS-3 activator or nitric oxide donor to increase the permeability of the blood brain barrier. By increasing the permeability of the blood barrier, a therapeutic or diagnostic compound can be delivered across this barrier into the central nervous system.